Notice of Half Year Results

RNS Number : 7362X

MaxCyte, Inc.

02 September 2020

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Half Year Results

Gaithersburg, Maryland - 2 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, will be announcing its half year financial results for the six months ended 30 June 2020 on Monday, 21 September 2020.

Doug Doerfler, Chief Executive Officer, will host a live briefing for analysts at 13.00pm BST on Monday, 21 September 2020. The presentation will be available on the Investors section of MaxCyte's website at https://www.maxcyte.com/investors/ .

A replay file will be made available shortly afterwards via the Company website.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit  www.maxcyte.com .

  Contacts:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	[phone]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns	[phone]
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith	[phone]
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Ashley Tapp --------------------------------------------------------------	[phone] maxcyte@consilium-com

 

END

 

 

NORUAOBRRAUKRAR